Vaccine Immunotherapy The institute is actively expanding vaccine research and immunotherapy, including an HIV vaccine candidate announced in 2026 and a two-vaccine strategy for T Cell Lymphoma, plus a new vaccinology hire. This signals strong potential for collaborations with biotech and pharma across early-stage development, translational research, and vaccine platform services. Opportunities include contract research, assay development, preclinical testing, and data analytics partnerships.

Healthcare Partnerships The ChristianaCare pancreatic cancer collaboration demonstrates openness to partnerships with healthcare systems for translational research and patient access to trials. Sales opportunities include joint research programs, clinical trial site arrangements, data integration, and donor-supported initiatives aligned with outcomes research and real-world data.

Leadership Transition With the CEO set to depart in 2027, there is potential for strategic, multi-year collaborations, joint centers of excellence, or sustained research initiatives. Build relationships at senior levels, explore joint appointments or shared governance models, and align with philanthropic and grant opportunities to ensure continuity.

Data Modernization The tech footprint and programming proficiency suggest readiness for data management, lab informatics, and analytics modernization. Potential offerings include cloud-based data platforms, LIMS or ELN integrations, computational biology support, and donor analytics to support both research operations and fundraising.

Fundraising Partnerships Mid-range nonprofit revenue and the use of Bloomerang point to opportunities to optimize donor engagement and sponsorships. Propose donor CRM enhancements, grants management, targeted campaigns, and industry sponsorship packages that align with ongoing research and translational initiatives.